

Name: Nelly Pitteloud  
 Work Address: Centre Hospitalier Universitaire Vaudois (CHUV)  
 Endocrinology, Diabetes, and Metabolism Service, (SA08 / 02 / 253)  
 Avenue de la Sallaz 8, CH-1011 Lausanne  
 Tel: +41 21 314 8027 Fax: +41 21 314 0630  
 e-mail: nelly.pitteloud@chuv.ch  
 Date of Birth: April 11, 1964  
 Marital Status: Married, 2 children  
 Nationality: Swiss

OrcID: <https://orcid.org/0000-0003-0971-3237>, ResearcherID: K-2709-2014

### Personal Statement

I am an endocrinologist with specialty training in reproductive endocrinology. I am also a translational researcher and my focus has been on the genetics of rare endocrine disorders. Presently, I am Head of Endocrinology, Diabetes & Metabolism and Pediatric Endocrinology at the CHUV and serve as the chair of a European consortium of clinicians, geneticists, basic scientists, and bioinformaticians focused on congenital GnRH deficiency.

### Education and Positions

1990 MD, University of Geneva Medical School  
 1990-1994 Resident, Internal Medicine, Fribourg Hospital  
 1994 Resident, Metabolic Unit, Guys Hospital, London, UK  
 1995-1996 Chief Resident, Internal Medicine, Geneva University Hospital  
 1996-1997 Resident, Internal Medicine, Diabetes Unit, Geneva University Hospital  
 1997-1998 Chief Resident, Internal Medicine, Diabetes Unit, Geneva University Hospital  
 1998-1999 Clinical Fellow, Endocrinology & Diabetes, Massachusetts General Hospital (MGH), Boston, MA  
 1999-2002 Clinical & Research Fellow, Reproductive Endocrinology, MGH, Boston, MA  
 2002 Instructor in Medicine, Harvard Medical School, Boston, MA  
 2003 Assistant in Medicine, Massachusetts General Hospital, Boston, MA  
 2005 Assistant Professor in Harvard Medical School, Boston, MA  
 2007 Associate Member, MGH Center of Human Genetic Research, Boston, MA  
 2010 Associate Professor, Harvard Medical School, Boston, MA  
 2010 Chief, Endocrine Diabetes & Metabolism service, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne  
 2010 Chief, Pediatric Endocrinology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne  
 2010 Professor in Medicine, University of Lausanne, Faculty of Biology & Medicine

### Awards and Honors:

1998 Denber Pinard Award  
 2000 Endocrine Fellows Foundation Award  
 2001 Endocrine Society MCR Travel Award  
 2001 Endocrine Society Merck Clinical Research Award  
 2004 Claflin Award, Massachusetts General Hospital (MGH)  
 2005 Poster of Distinction, MGH Clinical Research Day  
 2006 Poster of Distinction, MGH Clinical Research Day  
 2007 Poster of Distinction, MGH Clinical Research Day  
 2007 Best Abstract, European Pediatric Endocrine Society, Helsinki, FI

2009 Krane Award for Translational Research, Massachusetts General Hospital  
 2012 Best Abstract, European Pediatric Endocrine Society, Leipzig, DE  
 2012 Swiss National Science Foundation

### Editorial Activities

American Journal of Human Genetics, Clinical Endocrinology, Endocrinology,  
 European Journal of Human Genetics, International Journal of Andrology, Journal of Clinical  
 Endocrinology & Metabolism, Journal of Clinical Investigation, Molecular Endocrinology,  
 Swiss National Science Foundation grant reviewer, Nature

### Professional Societies

College of Physicians of Switzerland, Swiss Internal Medicine Society, Swiss Society for  
 Endocrinology and Diabetes, Massachusetts Medical Society, American Diabetes Association,  
 Endocrine Society, European Society of Endocrinology, European Society of Paediatric  
 Endocrinology, Fédération des Médecins Suisses, Société Vaudoise du diabète.

### Current Research Support

SNF IZSTZO\_202612 (co-PI: Pitteloud) 499'059 CHF Apr 2022 - Mar 2026  
*The Genetics of Congenital Hypogonadotropic Hypogonadism in Pakistan*  
 This project will focus on: (i) launching a collaboration with Pakistani medical doctors and geneticists  
 to identify patients with a central defect of infertility, more specifically with CHH; (ii) training female  
 Pakistani and Swiss scientists; iii) improving education, diagnosis and treatment of Pakistani patients  
 with disorders of puberty and infertility; (iv) identifying novel CHH genes that will illuminate a greater  
 biological understanding of reproduction.

SNF 310030B\_201275 (PI: Pitteloud) 907'990 CHF Apr 2021 - Mar 2025  
*The Neuroendocrine Control of Human Reproduction*  
 This project will focus on clinical, genetic and basic aspect of GnRH neuron biology, employing a  
 multidisciplinary and translational approach to address the current challenges in the field: (1) We  
 therefore propose to improve the early diagnosis of CHH by validating machine learning to  
 distinguish CDGP from CHH. (2) We aim to promote personalized medicine by demonstrating the  
 role of genetics in guiding clinical assessment. (3) We propose to combine WGS with transcriptomics  
 to increase the yield of molecular diagnosis and translate these findings in clinical genetics. (4)  
 Finally, we will use CHH patients-derived iPSC and genome editing technologies to functionally  
 validate the genetic makeup of each patient, along the evaluation of potential individualized  
 treatments.

Horizon 2020 Research and Innovation Action - #847941 (Co-PI: Pitteloud) Jan 2020 – Dec 2025  
 783'510 EUR  
*MiniNO - Associative mechanisms linking a defective minipuberty to the appearance of mental and  
 non-mental disorders: infantile NO replenishment as a new therapeutic possibility*  
 The miniNO project aims to identify the key causative mechanisms of the lifelong multimorbidity  
 associated with preterm birth. Prematurity is associated with alterations in the maturation of the  
 hypothalamic-pituitary-gonadal axis, and specifically with its transient activation during infancy,  
 known as minipuberty. MiniNO will study for the first time the association between premature birth  
 and alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities

that appear later on in life. MiniNO is expected to improve the quality of life of millions of prematurely born individuals and reduce the financial and societal burdens they impose.

SNF / Bridge "Discovery" 40B2-0\_187153 (Co-PIs: Pitteloud)  
848'176 CHF

Dec 2020 – Mar 2024

*SensoCort: A wearable device for real-time monitoring of cortisol in humans*

Wearable devices permit the minimally invasive or non-invasive measurement of analytes in biofluids such as interstitial fluid, saliva, tears and sweat. Optimally, these measurements will serve as surrogates for analyte concentrations in blood. This project will develop and validate the first of its kind wearable medical companion device for real-time cortisol monitoring in human sweat, under medical specifications and medical hypothesis validations. If successful, such unique wearable technology, called Lab on Skin, will have a strong impact not only for the field of endocrinology but can be extended to obesity management, and other stress related disorders.

SNF IZCOZO\_182958 (PI: Pitteloud) 319'564 CHF

Apr 2019 - Mar 2023

*Improving Cleft Lip/Palate management of care through genomic medicine*

Specific Aim 1: To identify novel genes implicated in syndromic and non-syndromic CLP. We propose to discovery novel gene using a combination of: (i) multi-plex families with CLP ; (ii) whole genome sequencing (WGS) to capture missing non-coding, regulatory, or variants impacting DNA structure/localization/folding; (iii) VariantMaster, a bioinformatic tool developed by one of our team member and employed successfully to discover the genetic causes of similar Mendelian disorders. Specific Aim 2: To elucidate the shared genetic basis between CLP and CHH. We aim to assess rare variants in CLP genes in a large CHH cohort by: (i) performing detailed phenotyping in a large CHH cohort with special attention on CLP; (ii) and assessing the enrichment of CLP associated genes in this large CHH cohort.

## Past Support

SNF 310030 173260 (PI: Pitteloud) 1'098'212 CHF

Apr 2017 - Mar 2021

*The Neuroendocrine Control of Human Reproduction*

This multi-disciplinary project will include clinical, human genetics, bioinformatics, and basic research and capitalize on cutting-edge technologies (next-generation sequencing, bioinformatics, mass spectrometry, and gene editing) and the established European network of experts in reproduction (COST Action BM1105, [www.gnrhnetwork.eu](http://www.gnrhnetwork.eu)) to achieve the following three aims: Aim 1: To enhance early diagnosis in patients with CHH by combining phenotypic, genetic, and molecular approaches. Aim 2: To further elucidate the genetic complexity of GnRH deficiency disorders. Aim 3: To validate the roles of cubilin (CUBN) and its co-receptor megalin (LRP2) in GnRH neuron biology.

CTI (Co-PI: Pitteloud) 340'000 CHF

Dec 2015 - Nov 2017

*EndoSLims - Full cycle genomic data management and analysis routines for the genetics of diabetes and other endocrine disorders*

This project links next-generation sequencing with bioinformatics pipelines and a tailored computerized laboratory information systems (SLiMS) to develop an integrated platform for molecular diagnostic testing of endocrine disorders

Role: Co-PI

SNF 31003A 153328 (PI: Pitteloud) 756'000 CHF

Apr 2014 - Mar 2017

*The neuroendocrine control of human reproduction*

This project uses next-generation sequencing (NGS) technologies and functional genomics to identify novel genes underlying congenital GnRH deficiency and reveal genetic overlaps across

developmental disorders. Additionally, NGS results are analyzed along with data from genome-wide association studies to identify novel genes controlling pubertal timing.

SNF IZLSZ3 148908 (Co-PI: Pitteloud) 229'000 CHF Jan 2014 - Dec 2016

*Exploring the molecular basis and phenotypic spectrum of reproductive disorders in South Africa*  
This project aims to investigate the genetic basis of reproductive disorders among a cohort of South African probands. Collaborative genotyping and phenotyping studies in concert with *in vitro* functionality studies are planned to elucidate the biology of novel genes identified in this unique population.

COST BM1105 (Chair & PI: Pitteloud) 180'000 CHF Apr 2012 - Mar 2016

European Collaboration in Science & Technology (COST)

*GnRH deficiency: Elucidation of the neuroendocrine control of human reproduction*

This project aims to create a European consortium of clinician investigators, basic scientists, geneticists, bioinformaticians, and genetic counselors interested in the study, diagnosis, treatment, and counseling of patients with delayed puberty and congenital GnRH deficiency.

CRSII3\_141960 (Co-PI: Pitteloud) 1'500'000 CHF Dec 2012 - Nov 2015

*SNF Sinergia: FGF21 is a link between reproduction and energy balance*

This interdisciplinary translational research grant includes 4 sub-projects. The project brings together investigators with expertise in human genetics (Pitteloud), circadian clock (Albrecht), structural biology (Mohammadi), and astrocyte biology (Pellerin) to elucidate the central role of FGF21 in energy sensing and a link between metabolism and reproduction.

SERI C12.0106 (PI: Pitteloud) 180'000 CHF Dec 2012 - Nov 2015

*Enhancing bioinformatic approaches for analysis of exome sequencing data generated from GnRH deficient patients*

This project aims to develop a targeted bioinformatic filtering/prioritizing pipeline to identify high-quality candidate genes for congenital hypogonadotropic hypogonadism. The resulting deliverable will be distributed to other European investigators via the funded COST action BM1105

SNF 31003A 135648 (PI: Pitteloud) 537'000 CHF Apr 2011 - Mar 2014

*The neuroendocrine control of human reproduction*

This project examines the role of the fibroblast growth factor 8 (FGF8) gene network and bone morphogenic proteins (BMPs) in the neuroendocrine control of reproduction. Multidisciplinary approaches incorporating the complementary fields of human genetics, molecular biology, and structural biology are employed.

5R01 HD 056264 (PI: Pitteloud) 1'300'000 \$ Jul 2008 - Jun 2013

*NIH-NICHD: Role of FGF signaling in neuroendocrine control of reproduction*

This translational research project aims to define the role of FGF8 signaling in GnRH development using an interdisciplinary approach including human genetics (and the human disease model of idiopathic hypogonadotropic hypogonadism [GnRH deficiency]), biochemistry, and structural biology.

RO1 DK 071168 (PI: Hayes/Pitteloud) 870'000 \$ Jul 2006 - Jun 2011

*NIH/NIDDK: Modulation of insulin action by testosterone in men*

The goals of this grant were to examine the impact of testosterone on insulin sensitivity in men and to assess the differential effects of testosterone and estradiol in men with the metabolic syndrome. This grant involved physiologic investigation, human genetic studies, and detailed metabolic phenotyping studies.

**Supervision of junior researchers***A. Master thesis*

- Vanessa Héritier (Master thesis). 2013-2015  
« Evaluation du rythme circadien du Fibroblast growth factor 21 (FGF21) chez les enfants pré-pubertaires obèses, avec un diabète de type 1 et normaux »
- Adelina Ameti (Master thesis). 2013-2015  
« Le syndrome des ovaires polykystiques chez les adolescentes obèses »
- Isaline Francey (Master thesis). 2013-2015  
« Hyperprolactinémie et désordres de la reproduction »
- Muriel Jeanmonod (Master thesis). 2013-2015  
« Diabète et troubles de la production de testostérone chez l'homme »
  
- Sylvain Rossier (Master thesis). 2013-2015  
« Caractéristiques cliniques et génétiques du syndrome de néoplasies endocriniennes multiples de type 1 »
- Lourenço Brian Lopes (Master thesis). 2016-2018  
« Caractérisation des patients avec maladie de Cushing et évaluation de leur réponse thérapeutique »
- Stephen Adjahou (Master thesis). 2016-2018  
« Etude rétrospective sur les patients atteints d'hypogonadisme hypogonadotrope au CHUV »
- Jean-David Muller (Master thesis). 2016-2018  
« PCOS » chez les adolescents
- David Naef (Master thesis). 2018-2020  
« Étude rétrospective sur les phénotypes des phéochromocytomes et demande prospective d'analyses génétiques B13 »
- Mathilde Sandmeier (Master thesis). 2018-2020  
« Variabilité phénotypique du syndrome des ovaires polykystiques chez les patientes suivies au CHUV »
- Damien Choffat (Master thesis). 2018-2020  
« Déficience en 21hydroxylase : de la génétique à la clinique »

*B. Former MD or PhD students*

- Andrew Dwyer (PhD). 2011-2014  
« Needs assessment in male GnRH deficient patients: A fundamental step to develop targeted nursing interventions aimed at enhancing health promoting behaviors and developing patient-centered approaches to care»
- Daniele Cassatella (PhD). 2012-2017  
« Bioinformatic approaches for analyzing exome sequencing data in patients with reproductive disorders »

- Cheng Xu (PhD). 2013-2017  
« Phenotype-genotype correlation and novel gene discovery in congenital hypogonadotropic hypogonadism »
- Santini Sara (MD) 2015-17 – «CHH genes discovery»
- Zosia Kolesinska (MD/PhD) 2018-2020 – «Genetic etiologies of disorders of sex development»
- Jesse Rademaker (PhD) 2019-2021 – «High-throughput approaches for CHH genes discovery»

#### *C. Present MD, Post-doc or PhD students*

- Adamo Michela (PhD) 2018 – «High-throughput approaches for CHH genes discovery»
- Antoniou Maria-Christina (MD) 2019 - «Differentiating constitutional delay of puberty and CHH»
- Yassine Zouaghi (PhD) 2020 – «Artificial Intelligence-based diagnostics and management of CHH»
- Dassine Berdous (Post-doc) 2020 – “Patients-derived IPS cells for GnRH neurons development modeling”

#### *D. Contributions to early careers of researchers*

- 2005-2007 Taneli Raivio, MD, PhD (post-doc) currently: Professor, University of Helsinki, Finland
- 2005-2007 Elka Jacobson-Dickman, MD (post-doc) currently: Fellowship Program Director & Associate - Director, Pediatric Endocrinology, Maimonides Medical Center, Brooklyn, USA
- 2008-2010 Cecilia Martin, PhD (post-doc) currently: Post-doc, Brigham & Womens Hospital, Boston, USA
- 2009-2010 Magdalena Avbelj, MD (post-doc) currently: Faculty, Pediatric endocrinology, University Medical Center Ljubljana, SL
- 2009-2010 Gerasimos Sykiotis, MD, PhD (post-doc) currently: Privat Docent & Faculty, Endocrinology, Diabetes & Metabolism, CHUV, Lausanne, CH
- 2010-2012 Hichem Miraoui, PhD (post-doc) currently: Post-doc, Harvard Medical School Dept. of Genetics, Boston, MA, USA
- 2011-2014 Andrew Dwyer (PhD student) currently: Assistant Professor, Boston College, Connell School of Nursing, Chestnut Hill, MA, USA
- 2013-2017 Emmanuel Somm PhD (Post-doc) currently: Research Associate, University of Geneva, CH
- 2013-2017 Cheng Xu MD-PhD (PhD) currently: Research associate, CHUV, Lausanne, CH
- 2014-2016 Sara Santini (MD) currently: Clinical fellow, CHUV, Lausanne, CH
- 2015-2017 Justine Bouilly (Post-Doc) currently: Biologist, CHUV, Lausanne, CH
- 2013-2018 Daniele Cassatella (PhD) currently: Bioinformatician, Synlab, Lausanne, CH
- 2017-2020 James Acierno Jr. (PhD) currently: Consultant in Genetics, Boston, USA & Lausanne, CH

## Teaching activities

Faculty of Biology and Medicine (UNIL/CHUV – Lausanne)

- B2.6. - Endocrinology of reproduction / neuroendocrinology  
(7h/year - since 2010)
- B3.5 - Growth and development: Puberty  
(1h/year - since 2013)
- B3.9 – Cours à option “Ni fille ni garçon - DSD à l’âge adulte »  
(3h/year - since 2015)
- M1.9 – Cours à option « L’hypophyse reine des glandes- introduction à la neuroendocrinologie, prolactinomes, acromégalie»  
(10h/year - since 2019)
- M2.2 - Chronic and complex diseases – Adrenal disease  
(3h/year - since 2011)
- Bachelor es Science en Biologie “Physiology of Complex Systems - Endocrinologie de la reproduction et métabolisme du glucose”  
(4h/year – Since 2014)
- Master of Science in Medical Biology (MSc) – Metabolism, diabetes and metabolic syndrome – glucose metabolism and diabetes  
(4h/year – since 2017)

## Publications

Web of science: 146 entries, H-index: 44, total 6597 citations (without self-citations), 66.3 per item.  
Google Scholar: H-index 56 (43 since 2017), total 12070 citations.

Publication List accessible at:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=pitteloud+n>

## **Original Peer-Reviewed Articles**

1. **Pitteloud N**, Binz K, Caulfield A, Philippe J. Ketoacidosis during gestational diabetes. Case report. *Diabetes Care*. 1998. 21(6):1031-2.
2. **Pitteloud N**, Philippe J. Characteristics of Caucasian type 2 diabetic patients during ketoacidosis and at follow-up. *Schweiz Med Wochenschr*. 2000. 130(16):576-82.
3. Beranova M, Oliveira LM, Bédécarrats GY, Schipani E, Vallejo M, Ammini AC, Quintos JB, Hall JE, Martin KA, Hayes FJ, **Pitteloud N**, Kaiser UB, Crowley WF, Seminara SB. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2001. 86(4):1580-8.
4. **Pitteloud N**, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF, Hayes FJ. The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. *J Clin Endocrinol Metab*. 2001. 86(6):2470-5.

5. Hayes FJ, **Pitteloud N**, DeCruz S, Crowley WF, Boepple PA. Importance of inhibin B in the regulation of FSH secretion in the human male. *J Clin Endocrinol Metab.* 2001. 86(11):5541-6.
6. **Pitteloud N**, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2002. 87(1):152-60.
7. **Pitteloud N**, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2002. 87:4128-36.
8. **Pitteloud N**, Villegas J, Dwyer AA, Crowley WF, McPhaul MJ, Hayes FJ. Acute stress masking the biochemical phenotype of partial androgen insensitivity syndrome in a patient with a novel mutation in the androgen receptor. *J Clin Endocrinol Metab.* 2004. 89(3):1053-8.
9. **Pitteloud N**, Acierno JS, Meysing AU, Dwyer AA, Hayes FJ, Crowley WF. Reversible Kallmann Syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the FGFR1 gene. *J Clin Endocrinol Metab.* 2005. 90(3):1317-22.
10. **Pitteloud N**, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab.* 2005. 90(5):2636-41.
11. **Pitteloud N**, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson K-F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ. Relationship between testosterone levels, insulin sensitivity and mitochondrial function in men. *Diabetes Care.* 2005. 28(7):1636-42.
12. Corssmit EPM, Seminara SB, **Pitteloud N**, Fliers E. Kallmann syndrome in a 47,XXX patient. *Am J Med Genet A.* 2005. 39(1):52-3. PMID: 16222664
13. Kumar, PA\*, **Pitteloud N\***, Andrews PA, Dwyer AA, Hayes F, Crowley WF, Dym M. Testis morphology in patients with idiopathic hypogonadotropic hypogonadism. *Hum Reprod.* 2006. 21:1033-40.(\* denotes co-first authors)
14. **Pitteloud N**, Acierno J.S, jr., Meysing A., Eliseenkova A.V., Ma J., Ibrahimi O.A., Metzger D., Hayes F.J., Dwyer A.A., Hughes V.A., Yialamas, M., Hall J.E., Grant E., Mohammadi M., Crowley W.F.Jr. 2006. Mutations in FGFR1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA.* 2006. 103:6281-6.
15. **Pitteloud N**, Meysing A, Quinton R, Acierno JS, Dwyer AA, Plummer L, Fliers E, Boepple PA, Hayes FJ, Seminara SB, Bouloux P, Mohammadi M, Crowley WF, Jr. . Mutations in Fibroblast Growth Factor Receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. *Mol Cell Endocrinol.* 2006. 254-255:60-9.
16. Pallais JC, Bo-Abbas Y, **Pitteloud N**, Crowley WF Jr, Seminara SB. . Neuroendocrine, gonadal, placental, and obstetric phenotypes in patients with IHH and mutations in the G-protein coupled receptor, GPR54. *Mol Cell Endocrinol.* 2006. 254-255:70-7.
17. Cerrato F, Shagoury J, Kralickova M, Dwyer A, Falardeau J, Ozata M, Van Vliet G, Bouloux P, Hall JE, Hayes FJ, **Pitteloud N**, Martin KA, Welt C, Seminara SB. Coding sequence analysis of GNRHR and GPR54 in patients with congenital and adult-onset forms of hypogonadotropic hypogonadism. *Eur J Endocrinol.* 2006. 155:Suppl 1:S3-S10.
18. **Pitteloud N**, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, Plummer L, Hughes V, Seminara S, Cheng YZ, Li WP, Maccoll G, Eliseenkova AV, Olsen SK, Ibrahimi OA, Hayes FJ, Boepple P, Hall JE, Bouloux P, Mohammadi M, Crowley W. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest.* 2007. 117:457-63.
19. Yialamas MA, Dwyer AA, Hanley E, Lee H, **Pitteloud N**, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2007. 92:4254-4259.
20. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, Lee H, Boepple P, Crowley WF, **Pitteloud N**. Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med.* 2007. 357:863-73.
21. **Pitteloud N**, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, Plummer L, Jacobson-Dickman EE, Mellon PL, Zhou QY, Crowley WF Jr. Loss-of-function mutation in the prokineticin 2 gene

- causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA*. 2007. 104:17447-52.
22. **Pitteloud N**, Dwyer AA, Decruz S, Lee H, Boepple PA, Crowley WF Jr, Hayes FJ. Inhibition of LH Secretion by Testosterone in Men Requires Aromatization for its Pituitary but not its Hypothalamic Effects: Evidence from the Tandem Study of Normal and Gonadotropin-Releasing Hormone-Deficient Men. *J Clin Endocrinol Metab*. 2008. 93:784-91.
  23. **Pitteloud N**, Dwyer AA, Decruz S, Lee H, Boepple PA, Crowley WF Jr, Hayes FJ. The Relative Role of Gonadal Sex Steroids and Gonadotropin-Releasing Hormone Pulse Frequency in the Regulation of FSH Secretion in Men. *J Clin Endocrinol Metab*. 2008. 93:2686-92.
  24. Boepple PA, Hayes FJ, Dwyer AA, Raivio T, Lee H, Crowley WF Jr, **Pitteloud N**. Relative roles of inhibin B and sex steroids in the negative feedback regulation of follicle-stimulating hormone in men across the full spectrum of seminiferous epithelium function. *Journal of Endocrinology and Metabolism*. 2008. 93:1809-14.
  25. Cole LW, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, Hughes VA, Dwyer AA, Raivio T, Hayes FJ, Seminara SB, Huot C, Alos N, Speiser P, Takeshita A, Van Vliet G, Pearce S, Crowley WF Jr, Zhou QY, **Pitteloud N**. Mutations in Prokineticin 2 (PROK2) and PROK2 Receptor (PROKR2) in Human Gonadotrophin-Releasing Hormone Deficiency: Molecular Genetics and Clinical Spectrum. *J Clin Endocrinol Metab*. 2008. 93:3551-59.
  26. Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman EE, Eliseenkova AV, Ma J, Dwyer A, Quinton R, Na S, Hall JE, Huot C, Alois N, Pearce SH, Cole LW, Hughes V, Mohammadi M, Tsai P, **Pitteloud N**. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. *J. Clin. Invest*. 2008. 118:2822-31.
  27. Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, **Pitteloud N**, Miller WT, Neubert TA, Mohammadi M. A crystallographic snapshot of tyrosine trans-phosphorylation in action. *Proc Natl Acad Sci USA*. 2008. 105:19660-5.
  28. Jongmans MC, van Ravenswaaij-Arts CM, **Pitteloud N**, Ogata T, Sato N, Claahsen-van der Grinten HL, van der Donk K, Seminara S, Bergman JE, Brunner HG, Crowley WF Jr, Hoefsloot LH. . CHD7 mutations in patients initially diagnosed with Kallmann syndrome--the clinical overlap with CHARGE syndrome. *Clin Genet*. 2009. 75:65-71.
  29. **Pitteloud N**, Thambundit A, Dwyer AA, Falardeau JL, Plummer L, Caronia LM, Hayes FJ, Lee H, Boepple PA, Crowley WF Jr. Role of seminiferous tubular development in determining the FSH versus LH responsiveness to GnRH in early sexual maturation. *Neuroendocrinology*. 2009. 90(3):260-8.
  30. Raivio T, Sidis Y, Plummer L, Chen H, Ma J, Mukherjee A, Jacobson-Dickman E, Quinton R, Van Vliet G, Lavoie H, Hughes VA, Dwyer A, Hayes FJ, Xu S, Sparks S, Kaiser UB, Mohammadi M, **Pitteloud N**. Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2009. 94(11):4380-90.
  31. Chan YM, de Guillebon A, Lang-Muritano M, Plummer L, Cerrato F, Tsiaras S, Gaspert A, Lavoie HB, Wu CH, Crowley WF Jr, Amory JK, **Pitteloud N**, Seminara SB. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA*. 2009. 106(28):11703-8.
  32. Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, Dwyer AA, Quinton R, Hall JE, Gusella JF, Seminara SB, Crowley WF Jr, **Pitteloud N**. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. *Proc Natl Acad Sci USA*. 2010. 107(34):15140-4. PMID:20696889
  33. Dwyer AA, Hayes FJ, Plummer L, **Pitteloud N**, Crowley WF Jr. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2010. 95(9):4235-43. PMID :20591981
  34. Trarbach EB, Abreu AP, Silveira LF, Garmes HM, Baptista MT, Teles MG, Costa EM, Mohammadi M, **Pitteloud N**, Mendonca BB, Latronico AC. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. *J Clin Endocrinol Metab*. 2010. 95(7):3491-6. PMID :20463092
  35. Sykiotis GP, Hoang XH, Avbelj M, Hayes FJ, Thambundit A, Dwyer A, Au M, Plummer L, Crowley WF Jr, **Pitteloud N**. Congenital idiopathic hypogonadotropic hypogonadism: evidence

- of defects in the hypothalamus, pituitary, and testes. *J Clin Endocrinol Metab.* 2010. 95(6):3019-27. PMID: 20382682
36. Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, Hughes VA, Seminara SB, Boepple PA, Sidis A, Crowley Jr WF, Martin KA, Hall JE, **Pitteloud N**. A genetic basis for functional hypothalamic amenorrhea. *N Engl J Med.* 2011. 364(3):215-25. PMID 21247312
  37. Martin C, Balasubramanian R, Dwyer AA, Au MG, Sidis Y, Kaiser UB, Seminara SB, **Pitteloud N**, Zhou QY, Crowley WF Jr. The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations. *Endocr Rev.* 2011. 32(2):225-46. PMID: 21037178
  38. Shaw ND, Seminara SB, Welt CK, Au MG, Plummer L, Hughes VA, Dwyer AA, Martin KA, Quinton R, Mericq V, Merino PM, Gusella JF, Crowley WF Jr, **Pitteloud N**, Hall JE. Expanding the phenotype and genotype of female GnRH deficiency. *J Clin Endocrinol Metab.* 2011. 96(3):E566-76. PMID: 21209029
  39. Trabado S, Maione L, Salenave S, Baron S, Galland F, Bry-Gaillard H, Guiochon-Mantel A, Chanson P, **Pitteloud N**, Sinisi AA, Brailly-Tabard S, Young J. Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. *Fertil Steril.* 2011. 95(7):2324-9, 2329.e1-3. Epub 2011 May 4. PMID: 21536274
  40. Tornberg J, Sykiotis GP, Keefe K, Plummer L, Hoang X, Hall JE, Quinton R, Seminara SB, Hughes V, Van Vliet G, Van Uum S, Crowley WF, Habuchi H, Kimata K, **Pitteloud N**, Bülow HE. Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA.* 2011. 108(28):11524-9. PMID: 21700882
  41. McCabe MJ, Gaston-Massuet C, Tziaferi V, Gregory LC, Alatzoglou KS, Signore M, Puelles E, Gerrelli D, Farooqi IS, Raza J, Walker J, Kavanaugh SI, Tsai PS, **Pitteloud N**, Martinez-Barbera JP, Dattani MT. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. *J Clin Endocrinol Metab.* 2011. 96(10):E1709-18. PMID: 21832120
  42. Chan YM, Broder-Fingert S, Paraschos S, Lapatto R, Au M, Hughes V, Bianco SD, Min L, Plummer L, Cerrato F, De Guillebon A, Wu IH, Wahab F, Dwyer A, Kirsch S, Quinton R, Cheetham T, Ozata M, Ten S, Chanoine JP, **Pitteloud N**, Martin KA, Schiffmann R, Van der Kamp HJ, Nader S, Hall JE, Kaiser UB, Seminara SB. GnRH-deficient phenotypes in humans and mice with heterozygous variants in KISS1/Kiss1. *J Clin Endocrinol Metab.* 2011. 96(11):E1771-81. PMID: 21880801
  43. Dessimoz C, Browaeys P, Maeder P, Lhermitte B, **Pitteloud N**, Momjian S, Pralong FP. Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma. *Front Endocrinol (Lausanne).* 2011. 2:116. PMID: 22654846
  44. Lewkowitz-Shpuntoff HM, Hughes VA, Plummer L, Au MG, Doty RL, Seminara SB, Chan YM, **Pitteloud N**, Crowley WF Jr, Balasubramanian R. Olfactory phenotypic spectrum in idiopathic hypogonadotropic hypogonadism: Pathophysiological and genetic implications. *J Clin Endocrinol Metab.* 2012. 97(1):E136-44. PMID:22072740
  45. Raivio T, Avbelj M, McCabe MJ, Romero CJ, Dwyer AA, Tommiska J, Sykiotis GP, Gregory LC, Diaczok D, Tziaferi V, Elting MW, Padidela R, Plummer L, Martin C, Feng B, Zhang C, Zhou QY, Quinton R, Sidis Y, Radovick S, Dattani MT, **Pitteloud N**. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. *J Clin Endocrinol Metab.* 2012. 97(4):E694-9. PMID:22319038
  46. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J, Ma J, Gai W, Sidis Y, **Pitteloud N**, Kuro-O M, Razzaque MS, Mohammadi M. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. *Mol Cell Biol.* 2012. 32(10):1944-54. PMID: 22451487
  47. Gianetti E, Hall JE, Au MG, Kaiser UB, Quinton R, Stewart JA, Metzger DL, **Pitteloud N**, Mericq V, Merino PM, Levitsky LL, Izatt L, Lang-Muritano M, Fujimoto VY, Dluhy RG, Chase ML, Crowley WF Jr, Plummer L, Seminara SB. When genetic load does not correlate with phenotypic spectrum: lessons from the GnRH receptor (GNRHR). *J Clin Endocrinol Metab.* 2012. 97(9):E1798-807. PMID:22745237

48. Avbelj Stefanija M, Jeanpierre M, Sykiotis GP, Young J, Quinton R, Abreu AP, Plummer L, Au MG, Balasubramanian R, Dwyer AA, Florez JC, Cheetham T, Pearce SH, Purushothaman R, Schinzel A, Pugeat M, Jacobson-Dickman EE, Ten S, Latronico AC, Gusella JF, Dode C, Crowley WF Jr, **Pitteloud N**. An ancient founder mutation in PROKR2 impairs human reproduction. *Hum Mol Genet.* 2012. 19:4314-24. PMID 22773735
49. Caronia LM, Dwyer AA, Hayden D, Amati F, **Pitteloud N**, Hayes FJ. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. *Clin Endocrinol (Oxf).* 2012. 78(2): 291-296. PMID 22804876
50. Koika V, Varnavas P, Valavani H, Sidis Y, Plummer L, Dwyer A, Quinton R, Kanaka-Gantenbein C, **Pitteloud N**, Sertedaki A, Dacou-Voutetakis C, Georgopoulos NA. Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH). *Gene.* 2013. 516(1):146-51. PMID:23276709
51. Abel BS, Shaw ND, Brown JM, Adams JM, Alati T, Martin KA, **Pitteloud N**, Seminara SB, Plummer L, Pignatelli D, Crowley WF Jr, Welt CK, Hall JE. Responsiveness to a physiological regimen of GnRH therapy and relation to genotype in women with isolated hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 98:E206-16, 2013 *J Clin Endocrinol Metab.* 2013. 98(2):E206-16. PMID:23341491
52. McCabe MJ, Gaston-Massuet C, Gregory LC, Alatzoglou KS, Tziaferi V, Sbai O, Rondard P, Masumoto KH, Nagano M, Shigeyoshi Y, Pfeifer M, Hulse T, Buchanan CR, **Pitteloud N**, Martinez-Barbera JP, Dattani MT. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. *J Clin Endocrinol Metab.* 2013. 98(3):E547-57. PMID:23386640
53. Costa-Barbosa FA, Balasubramanian R, Keefe KW, Shaw ND, Al-Tassan N, Plummer L, Dwyer AA, Buck CL, Choi JH, Seminara SB, Quinton R, Monies D, Meyer B, Hall JE, **Pitteloud N**, Crowley WF Jr. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. *J Clin Endocrinol Metab.* 2013. 98(5):E943-53. PMID:23533228
54. Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley WF Jr, Seminara SB, Quinton R, Hughes VA, Kumanov P, Young J, Yialamas MA, Hall JE, Van Vliet G, Chanoine JP, Rubenstein J, Mohammadi M, Tsai PS, Sidis Y, Lage K, **Pitteloud N**. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. *Am J Hum Genet.* 2013. 92(5):725-43. PMID:23643382
55. Wiehle R, Cunningham GR, **Pitteloud N**, Wike J, Hsu K, Fontenot GK, Rosner M, Dwyer A, Podolski J. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. *BJU Int.* 2013 Jul 12. doi: 10.1111/bju.12363. PMID: 23875626
56. Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Sluss PM, Crowley WF Jr, **Pitteloud N**. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2013. 98(11):E1790-5. PMID: 24037890
57. Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, Plummer L, Dwyer A, **Pitteloud N**, Hayes FJ, Hall JE, Martin KA, Boepple PA, Seminara SB. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. *J Clin Endocrinol Metab.* 2014. 99(3):861-70. PMID: 24423288
58. Balasubramanian R, Cohen DA, Klerman EB, Pignatelli D, Hall JE, Dwyer AA, Czeisler CA, **Pitteloud N**, Crowley WF. Absence of central circadian pacemaker abnormalities in humans with loss of function mutation in prokineticin 2. *J Clin Endocrinol Metab.* 2014. 99(3):E561-6. PMID: 24423319
59. Käsäkoski J, Fagerholm R, Laitinen EM, Vaaralahti K, Hackman P, **Pitteloud N**, Raivio T, Tommiska J. Mutation screening of SEMA3A and SEMA7A in patients with congenital hypogonadotropic hypogonadism. *Pediatr Res.* 2014; 75(5):641-4. PMID: 2452209
60. Dwyer AA, Quinton R, Morin D, **Pitteloud N**. Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment:

- implications for online interventions and peer-to-peer support. *Orphanet J Rare Dis.* 2014 Jun 11;9 (1):83. PMID:24915927
61. Villanueva C\*, Jacobson-Dickman E\*, Cheng Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, Beenken A, Liu Y, Tommiska J, Hu Y, Tiosano D, Gerard M, Leger J, Drouin-Garraud V, Lefebvre H, Polak M, Carel JC, Phan-Hug F, Hauschild M, Plummer L, Rey JP, Raivio TBouloux P, Sidis Y, Mohammadi M, de Roux N, **Pitteloud N**. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. *Genet Med.* 2014. Aug;17(8):651-9. (\* denotes co-first authorship) PMID:25394172
  62. Deillon E, Hauschild M, Faouzi M, Stoppa-Vaucher S, Elowe-Gruau E, Dwyer A, Theintz GE, Dubuis JM, Mullis PE, **Pitteloud N**, Phan-Hug F. Natural History of Growth Hormone Deficiency in a Pediatric Cohort. *Horm Res Paediatr.* 2015. 83(4):252-61. PMID: 25676059
  63. Correa FA, Trarbach EB, Tusset C, Latronico AC, Montenegro LR, Carvalho LR, Franca MM, Otto AP, Costalonga EF, Brito VN, Abreu AP, Nishi MY, Jorge AA, Arnhold IJ, Sidis Y, **Pitteloud N**, Mendonca BB. FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies. *Endocr Connect.* 2015. Jun;4(2):100-7. PMID: 25759380
  64. Dwyer A, Quinton R, **Pitteloud N**, Morin D. Psychosexual development in men with congenital hypogonadotropic hypogonadism on long-term treatment: A mixed-methods study. *Sex Med.* 2015. Mar; 3(1):32-41. PMID: 25844173
  65. Ducry J, Gomez F, Prior JO, Boubaker A, Matter M, Monti M, Pu Y, **Pitteloud N**, Portmann L. Mid-gut ACTH-secreting neuroendocrine tumor unmasked with (18)F-dihydroxyphenylalanine-positron emission tomography. *Endocrinol Diabetes Metab Case Rep.* 2015:140104. PMID: 25861450
  66. Tommiska J, Känsäkoski J, **Pitteloud N**, Wu F, Raivio T. Gonadotropin-releasing hormone receptor mutations in ageing men. *Clin Endocrinol (Oxf).* 2016 Jan;84(1):150-1. doi: 10.1111/cen.12833. Epub 2015 Jul 1. No abstract available. PMID: 26044071
  67. Dwyer A, Tiemensma J, Quinton R, **Pitteloud N**, Morin D. Adherence to treatment in men with hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf).* 2017 Mar;86(3):377-383. doi: 10.1111/cen.13236. Epub 2017 Jan 11. PMID: 27647266.
  68. Chavan R, Preitner N, Okabe T, Strittmatter LM, Xu C, Ripperger JA, **Pitteloud N**, Albrecht U. REV-ERB $\alpha$  regulates Fgf21 expression in the liver via hepatic nuclear factor 6. *Biol Open.* 2017 Jan 15;6(1):1-7. doi: 10.1242/bio.021519. PMID: 27875243.
  69. Xu C, Lang-Muritano M, Phan-Hug F, Dwyer AA, Sykiotis GP, Cassatella D, Acierno J Jr, Mohammadi M, **Pitteloud N**. Genetic testing facilitates prepubertal diagnosis of congenital hypogonadotropic hypogonadism. *Clin Genet.* 2017 Feb 14. doi: 10.1111/cge.12996. [Epub ahead of print] PMID: 28195315.
  70. Christou F, **Pitteloud N**, Gomez F. The induction of ovulation by pulsatile administration of GnRH: an appropriate method in hypothalamic amenorrhea. *Gynecol Endocrinol.* 2017 Mar 6:1-4. doi: 10.1080/09513590.2017.1296948. [Epub ahead of print] PMID: 28277105.
  71. COST Action BM1105., Badiu C, Bonomi M, Borshchevsky I, Cools M, Craen M, Ghervan C, Hauschild M, Hershkovitz E, Hrabovszky E, Juul A, Kim SH, Kumanov P, Lecumberri B, Lemos MC, Neocleous V, Niedziela M, Djurdjevic SP, Persani L, Phan-Hug F, Pignatelli D, **Pitteloud N**, Popovic V, Quinton R, Skordis N, Smith N, Stefanija MA, Xu C, Young J, Dwyer AA. Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital\_hypogonadotropic hypogonadism. *Orphanet J Rare Dis.* 2017 Mar 20;12(1):57. doi: 10.1186/s13023-017-0608-2. PMID: 28320476.
  72. Marcos S, Monnier C, Rovira Algans X, Fouveaut C, **Pitteloud N**, Ango F, Dodé C, Hardelin JP. Defective signaling through plexin-A1 compromises the development of the peripheral olfactory system and neuroendocrine reproductive axis in mice. *Hum Mol Genet.* 2017 Mar 2. doi: 10.1093/hmg/ddx080. [Epub ahead of print] PMID: 28334861.
  73. Somm E, Henry H, Bruce SJ, Aeby S, Rosikiewicz M, Sykiotis GP, Asrih M, Jornayvaz FR, Denechaud PD, Albrecht U, Mohammadi M, Dwyer A, Acierno JS Jr, Schoonjans K, Fajas L, Greub G, **Pitteloud N**.  $\beta$ -Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. *JCI Insight.* 2017 Apr 20;2(8). pii: 91809. doi: 10.1172/jci.insight.91809. [Epub ahead of print] PMID: 28422755

74. Corcillo A, Pivin E, Lalubin F, **Pitteloud N**, Burnier M, Zanchi A. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices. *Swiss Med Wkly*. 2017 Jul 11;147:w14459. doi: smw.2017.14459. eCollection 2017 Jul 11. PMID: 28695552.
75. Dzemaili S, Tiemensma J, Quinton R, **Pitteloud N**, Morin D, Dwyer A. Beyond hormone replacement: quality of life in women with congenital hypogonadotropic hypogonadism. *Endocr Connect*. 2017 Aug;6(6):404-412. PMID: 28698240.
76. Xu C, Messina A, Somm E, Miraoui H, Kinnunen T, Acierno J Jr, Niederländer NJ, Bouilly J, Dwyer AA, Sidis Y, Cassatella D, Sykiotis GP, Quinton R, De Geyter C, Dirlwanger M, Schwitzgebel V, Cole TR, Toogood AA, Kirk JM, Plummer L, Albrecht U, Crowley WF Jr, Mohammadi M, Tena-Sempere M, Prevot V, **Pitteloud N**. KLB, encoding  $\beta$ -Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. *EMBO Mol Med*. 2017. Oct;9(10):1379-1397. PMID: 28754744.
77. Tommiska J, Käsäkoski J, Skibsbye L, Vaaralahti K, Liu X, Lodge EJ, Tang C, Yuan L, Fagerholm R, Kanters JK, Lahermo P, Kaunisto M, Keski-Filppula R, Vuoristo S, Pulli K, Ebeling T, Valanne L, Sankila EM, Kivirikko S, Lääperi M, Casoni F, Giacobini P, Phan-Hug F, Buki T, Tena-Sempere M, **Pitteloud N**, Veijola R, Lipsanen-Nyman M, Kaunisto K, Mollard P, Andoniadou CL, Hirsch JA, Varjosalo M, Jespersen T, Raivio T. Two missense mutations in KCNQ1 cause pituitary hormone deficiency and maternally inherited gingival fibromatosis. *Nat Commun*. 2017. Nov 3;8(1):1289. PMID: 2909770.
78. Xu C, Cassatella D, van der Sloot AM, Quinton R, Hauschild M, De Geyter C, Flück C, Feller K, Bartholdi D, Nemeth A, Halperin I, Pekic Djurdjevic S, Maeder P, Papadakis G, Dwyer AA, Marino L, Favre L, Pignatelli D, Niederländer NJ, Acierno J Jr, **Pitteloud N**. Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants. *Genet Med*. 2017. Nov 16. doi: 10.1038/gim.2017.197. PMID: 29144511.
79. Bouilly J, Messina A, Papadakis G, Cassatella D, Xu C, Acierno JS, Tata B, Sykiotis G, Santini S, Sidis Y, Elowe-Gruau E, Phan-Hug F, Hauschild M, Bouloux PM, Quinton R, Lang-Muritano M, Favre L, Marino L, Giacobini P, Dwyer AA, Niederländer NJ, **Pitteloud N**. DCC/NTN1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron development. *Hum Mol Genet*. 2018. Jan 15;27(2):359-372. PMID: 29202173.
80. Cassatella D, Howard SR, Acierno JS, Xu C, Papadakis GE, Santoni FA, Dwyer AA, Santini S, Sykiotis GP, Chambion C, Meylan J, Marino L, Favre L, Li J, Liu X, Zhang J, Bouloux PM, Geyter C, Paepe A, Dhillon WS, Ferrara JM, Hauschild M, Lang-Muritano M, Lemke JR, Flück C, Nemeth A, Phan-Hug F, Pignatelli D, Popovic V, Pekic S, Quinton R, Szinnai G, l'Allemand D, Konrad D, Sharif S, Iyidir ÖT, Stevenson BJ, Yang H, Dunkel L, **Pitteloud N**. Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures. *Eur J Endocrinol*. 2018. Apr;178(4):377-388. PMID: 29419413.
81. Somm E, Henry H, Bruce SJ, Bonnet N, Montandon SA, Niederländer NJ, Messina A, Aeby S, Rosikiewicz M, Fajas L, Sempoux C, Ferrari SL, Greub G, **Pitteloud N**.  $\beta$ -Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice. *Am J Physiol Endocrinol Metab*. 2018. Jun 26. PMID: 29944388
82. Hansen EA, Klee P, Dirlwanger M, Bouthors T, Elowe-Gruau E, Stoppa-Vaucher S, Phan-Hug F, Antoniou MC, Pasquier J, Dwyer AA, **Pitteloud N**, Hauschild M. Accuracy, satisfaction and usability of a flash glucose monitoring system among children and adolescents with type 1 diabetes attending a summer camp. *Pediatr Diabetes*. 2018. Nov;19(7):1276-1284. PMID: 30014625
83. Favre L, Marino L, Roth A, Acierno J Jr, Hans D, Demartines N, **Pitteloud N**, Suter M, Collet TH. The Reduction of Visceral Adipose Tissue after Roux-en-Y Gastric Bypass Is more Pronounced in Patients with Impaired Glucose Metabolism. *Obes Surg*. 2018. Dec;28(12):4006-4013. PMID: 30109666
84. Kolesinska Z, Acierno J, Ahmed SF, Xu C, Kapczuk K, Skorczyk-Werner A, Mikos H, Rojek A, Massouras A, Krawczyński M, **Pitteloud N**, Niedziela M. Integrating clinical and genetic approaches in the diagnosis of 46, XY disorder of sex development. *Endocr Connect*. 2018. Nov 1. pii: EC-18-0472. PMID: 30496128

85. Antoniou MC, Bouthors T, Xu C, Phan-Hug F, Elowe-Gruau E, Stoppa-Vaucher S, Sloot AV, Acierno J, Cassatella D, Richard C, Dwyer A, **Pitteloud N**, Hauschild M. A novel CHD7 mutation in an adolescent presenting with growth and pubertal delay. *Ann Pediatr Endocrinol Metab.* 2019. 24(1):49-54. PMID: 30943680
86. Surbone A, Vaucher L, Primi MP, Leyvraz C, **Pitteloud N**, Ballabeni P, Mathevet P, Vulliamoz N. Clomiphene citrate effect on testosterone level and semen parameters in 18 infertile men with low testosterone level and normal/low gonadotropines level. *Eur J Obstet Gynecol Reprod Biol.* 2019. 238:104-109. PMID: 31128532
87. Dwyer AA, Chavan NR, Lewkowitz-Shpuntoff H, Plummer L, Hayes FJ, Seminara SB, Crowley WF, **Pitteloud N**, Balasubramanian R. Functional Hypogonadotropic Hypogonadism in Men: Underlying Neuroendocrine Mechanisms and Natural History. *J Clin Endocrinol Metab.* 2019. Aug 1;104(8):3403-3414. PMID: 31220265
88. Malone SA, Papadakis GE, Messina A, Mimouni NEH, Trova S, Imbernon M, Allet C, Cimino I, Acierno J, Cassatella D, Xu C, Quinton R, Szinnai G, Pigny P, Alonso-Cotchico L, Masgrau L, Maréchal JD, Prevot V, **Pitteloud N\***, Giacobini P\*. Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism. *Elife.* 2019. Jul 10;8. pii: e47198. PMID: 31291191 \* Contributed equally
89. Maione L, Pala G, Bouvattier C, Trabado S, Papadakis G, Chanson P, Bouligand J, **Pitteloud N**, Dwyer AA, Maghnie M, Young J. Congenital hypogonadotropic hypogonadism/Kallmann Syndrome is associated with statural gain in both men and women: a monocentric study. *Eur J Endocrinol.* 2019. Nov 1. PMID: 31770102
90. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, **Pitteloud N**, Lamine F. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. *BMC Endocr Disord.* 2019. Dec 23;19(1):144. PMID: 31870373
91. Messina A, Pulli K, Santini S, Acierno J, Käsäkoski J, Cassatella D, Xu C, Casoni F, Malone SA, Ternier G, Conte D, Sidis Y, Tommiska J, Vaaralahti K, Dwyer A, Gothif Y, Merlo GR, Santoni F, Niederländer NJ, Giacobini P, Raivio T, **Pitteloud N**. Neuron-Derived Neurotrophic factor is mutated in Congenital hypogonadotropic hypogonadism. *Am J Hum Genet.* 2020 Jan 2;106(1):58-70. PMID: 31883645
92. Zwingli G, Yerly J, Mivelaz Y, Stoppa-Vaucher S, Dwyer AA, **Pitteloud N**, Stuber M, Hauschild M. Non-invasive assessment of coronary endothelial function in children and adolescents with type 1 diabetes mellitus using isometric handgrip exercise-MRI: A feasibility study. 2020. *PLoS One.* Feb 13;15(2):e0228569. PMID: 32053613
93. Barraud S, Delemer B, Poirsier-Violle C, Bouligand J, Mérol JC, Grange F, Higel-Chaufour B, Decoudier B, Zalzali M, Dwyer AA, Acierno JS, **Pitteloud N**, Millar RP, Young J. Congenital hypogonadotropic hypogonadism with anosmia and Gorlin features caused by a PTCH1 mutation reveals a new candidate gene for Kallmann syndrome. *Neuroendocrinology.* 2020 Feb 20. PMID: 32074614
94. Papadakis GE, Dumont A, Bouligand J, Chasseloup F, Raggi A, Catteau-Jonard S, Boute-Benejean O, **Pitteloud N**, Young J, Dewailly D. 2020. Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. *Hum Reprod.* 2020 Apr 28;35(4):939-949. PMID: 32242900
95. Acierno JS, Xu C, Papadakis GE, Niederländer NJ, Rademaker JD, Meylan J, Messina A, Kolesinska Z, Quinton R, Lang-Muritano M, Bartholdi D, Halperin I, De Geyter C, Bouligand J, Bartoloni L, Young J, Santoni FA, **Pitteloud N**. Pathogenic mosaic variants in congenital hypogonadotropic hypogonadism. *Genet Med.* 2020. 22(11):1759-1767. PMID: 32724172
96. Abbara A, Eng PC, Phylactou M, Clarke SA, Mills E, Chia G, Yang L, Izzi-Engbeaya C, Smith N, Jayasena CN, Comninou AN, Anand-Ivell R, Rademaker J, Xu C, Quinton R, **Pitteloud N**, Dhillon WS. Kisspeptin-54 accurately identifies hypothalamic GnRH neuronal dysfunction in men with congenital hypogonadotropic hypogonadism. *Neuroendocrinology.* 2020. Online ahead of print. PMID: 33227799
97. Ostertag A, Papadakis GE, Collet C, Trabado S, Maione L, **Pitteloud N**, Bouligand J, De Vernejoul MC, Cohen-Solal M, Young J. Compromised Volumetric Bone Density and

- Microarchitecture in men with Congenital Hypogonadotropic Hypogonadism. 2021. *J Clin Endocrinol Metab*. Online ahead of print. PMID: 33725720
98. Salamin O, Nicoli R, Langer T, Boccard J, Grundisch CS, Xu C, Rudaz S, Kuuranne T, **Pitteloud N**, Saugy M. Longitudinal evaluation of multiple biomarkers for the detection of testosterone gel administration in women with normal menstrual cycle. 2021. *Drug Test Anal*. PMID: 33817997
  99. Marino L, Messina A, S Acierno J, Phan-Hug F, J Niederländer N, Santoni F, La Rosa S, **Pitteloud N**. Testosterone-induced increase in libido in a patient with a loss-of-function mutation in the AR gene. 2021. *Endocrinol Diabetes Metab Case Rep*. Jun 1;2021:21-0031. PMID: 34152287
  100. Salamin O, Nicoli R, Xu C, Boccard J, Rudaz S, **Pitteloud N**, Saugy M, Kuuranne T. Steroid profiling by UHPLC-MS/MS in dried blood spots collected from healthy women with and without testosterone gel administration. 2021. *J Pharm Biomed Anal*. Sep 10;204:114280. PMID: 34340018
  101. Santini S, Vionnet N, Pasquier J, Suter M, Hans D, Gonzalez-Rodriguez E, **Pitteloud N**, Favre L. Long-term body composition improvement in post-menopausal women following bariatric surgery: a cross-sectional and case-control study. 2022. *Eur J Endocrinol*. Jan 6;186(2):255-263. PMID: 34879003
  102. Al-Jawahiri R, Foroutan A, Kerkhof J, McConkey H, Levy M, Haghshenas S, Rooney K, Turner J, Shears D, Holder M, Lefroy H, Castle B, Reis LM, Semina EV; University of Washington Centre for Mendelian Genomics (UW-CMG), Lachlan K, Chandler K, Wright T, Clayton-Smith J, Hug FP, **Pitteloud N**, Bartoloni L, Hoffjan S, Park SM, Thankamony A, Lees M, Wakeling E, Naik S, Hanker B, Girisha KM, Agolini E, Giuseppe Z, Alban Z, Tessarech M, Keren B, Afenjar A, Zweier C, Reis A, Smol T, Tsurusaki Y, Nobuhiko O, Sekiguchi F, Tsuchida N, Matsumoto N, Kou I, Yonezawa Y, Ikegawa S, Callewaert B, Freeth M; Genomics England Research Consortium, Kleinendorst L, Donaldson A, Alders M, De Paepe A, Sadikovic B, McNeill A. SOX11 variants cause a neurodevelopmental disorder with infrequent ocular malformations and hypogonadotropic hypogonadism and with distinct DNA methylation profile. 2022. *Genet Med*. Mar 24:S1098-3600(22)00665-7. PMID: 35341651
  - 103.

### Reviews/Chapters/Editorials

1. **Pitteloud N**, Philippe J. Risque Coronarien chez les Diabétiques: effets préventifs des statines. *Médecine et Hygiène*. 1998. 56:529-36.
2. Hayes FJ, **Pitteloud N**. Hypogonadotropic Hypogonadism and Gonadotropin Therapy. In: *The Endocrinology of the Male* (McLachlan R ed.) www@endotext.org; 2001.
3. **Pitteloud N**, Crowley WF Jr. Congenital Hypogonadotropic Hypogonadism: Clinical Features and Pathophysiology. *Endocrinology Series: Hypogonadism: Basic, Clinical, and Therapeutic Principles*. 2005.
4. Pallais JC, Au M, **Pitteloud N**, Seminara S, Crowley WF Jr. Kallmann Syndrome (online chapter). In: Pagon RA, Adam MP, Bird TC, Dolan CR, Fong CT, Stephens K, editors. *Gene Reviews* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. 2007 May 23 [updated 2010 Oct 14]. PMID: 20301509
5. Pallais JC, Caudill M, **Pitteloud N**, Seminara S, Crowley, Jr WF. Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency Overview). In: Pagon RA, Adam MP, Bird TC, Dolan CR, Fong CT, Stephens K, editors. *Gene Reviews* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. 2007 May 23 [updated 2010 Oct 14]. PMID: 20301455
6. Crowley WF Jr, **Pitteloud N**, Seminara S. New genes controlling human reproduction and how you find them. *Trans Am Clin Climatol Assoc*. 2008. 119:29-37. PMID: 18596868

7. Balasubramanian R, Dwyer A, Seminara SB, **Pitteloud N**, Kaiser UB, Crowley WF Jr. Human GnRH deficiency: a unique disease model to unravel the ontogeny of GnRH neurons. *Neuroendocrinology*. 2010. 92(2):81-99. PMID: 20606386
8. Sykiotis GP, **Pitteloud N**, Seminara SB, Kaiser UB, Crowley WF Jr. Deciphering genetic disease in the genomic era: the model of GnRH deficiency. *Sci Transl Med*. 2010 May 19;2(32):32rv2. PMID: 20484732
9. **Pitteloud N**, Durrani S, Raivio T, Sykiotis GP Complex genetics in idiopathic hypogonadotropic hypogonadism. *Front Horm Res*. 2010. 39:142-53. PMID: 20389092
10. Mitchell AL, Dwyer A, **Pitteloud N**, Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. *Trends Endocrinol Metab* 2011 Jul;22(7):249-58. Epub 2011 Apr 20. PMID: 21511493
11. Miraoui H, Dwyer A, **Pitteloud N**. Role of fibroblast growth factor (FGF) signaling in the neuroendocrine control of human reproduction. *Mol Cell Endocrinol*. 2011. 346(1-2) :37-43. PMID: 21664428
12. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012. Jul 26 ; 367(4):319-28. PMID: 22686416
13. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggioni AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med*. 2012. Jul 26 ; 367(4):309-18. PMID: 22686415
14. Balasubramanian R, Plummer L, Sidis Y, **Pitteloud N**, Martin C, Zhou QY, Crowley WF Jr. The puzzles of the prokineticin 2 pathway in human reproduction. *Mol Cell Endocrinol*. 2011. Oct 22;346(1-2) :44-50. Epub 2011 Jun 1. PMID: 21664414
15. Phan-Hug F, Hauschild M, Dwyer A, **Pitteloud N**. [Caring for patients with pediatric endocrinopathies and diabetes into adulthood: challenges of an often difficult transition]. *Rev Med Suisse*. 2012. Nov 14;8(362):2170-2. PMID:23240318.
16. Blum MR, Collet TH, Krebs D, Stettler C, Christ E, Virgini V, Sykiotis G, Frey P, Reichenbach S, Boulat O, Mooser V, Jüni P, Fiedler M, Aujesky D, **Pitteloud N**, Rodondi N. Hypothyroïdie infraclinique. *Forum Medical Suisse*. 2013. 13(39):772-775.
17. Zanchi A, Cherpillod A, **Pitteloud N**, Burnier M, Pruijm M. Insuffisance rénale et diabète, les précautions à prendre. *Forum Med Suisse*. 2014. 14(06):100-104
18. **Pitteloud N**. Managing delayed or altered puberty in boys. *BMJ (clinical Research Ed.)* 2012. 345 pp. e7913. PMID:23207503.
19. Virgini V, Baumgartner C, Bischoff T, Haller DM, Frey P, Rosemann T, Collet TH, Sykiotis G, **Pitteloud N**, Rodondi N. [How do Swiss family physicians treat subclinical hypothyroidism?]. *Rev Med Suisse*. 2014. 10(420):526-9. PMID: 24701670.
20. Elowe-Gruau E, Phan-Hug F, Stoppa-Vaucher S, **Pitteloud N**, Hauschild M. [Follow-up and management of children born small for gestational age a endocrine and metabolic aspects]. *Rev Med Suisse*. 2014. 10(418):426-9. PMID: 24640277.
21. **Pitteloud N**, Dwyer A. Hormonal control of spermatogenesis in men: Therapeutic aspects in hypogonadotropic hypogonadism. *Ann Endocrinol (Paris)*. 2014. 75(2):98-100. PMID: 24793994.
22. Dwyer AA, Riavio T, **Pitteloud N**. Gonadotropin replacement for induction of fertility in hypogonadal men. *Best Pract Res Clin Endocrinol Metab* 2015. 29(1):91-103. PMID: 25617175.
23. Dwyer AA, Phan-Hug F, Hauschild M, Elowe-Gruau E, **Pitteloud N**. Transition in endocrinology: Hypogonadism in adolescence. *Eur J Endocrinol*. 2015. 173(1):R15-R24. PMID:2565325.
24. Hayes F, Dwyer A, **Pitteloud N**. Hypogonadotropic Hypogonadism (Hh) and Gonadotropin Therapy. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. *Endotext [Internet]*. South Dartmouth (MA): MDText.com, Inc.; 2000-.2013 Nov 25. PMID: 25905304.
25. Tran C, Barbey F, **Pitteloud N**, Philippe J, Kern I, Bonafé L. [Inborn errors of metabolism: transition from childhood to adulthood]. *Rev Med Suisse*. 2015. Feb 18;11(462):445-9. PMID: 25915985.

26. Xu C, Marino L, **Pitteloud N**. Hypogonadisme chez l'homme. *Forum Med Suisse*. 2015. 15(10):218-224
27. Boehm U, Bouloux PM, Dattani M, de Roux N, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin J-P, Juul A, Maghnie M, **Pitteloud N**, Prevot V, Quinton R, Raivio T, Tena-Sempere M, Young J. European consensus statement on congenital hypogonadotropic hypogonadism - pathogenesis, diagnosis, and treatment. *Nat Rev Endocrinol*. 2015. 11(9):547-64. PMID: 26194704.
28. Dwyer AA, Raivio T, **Pitteloud N**. MANAGEMENT OF ENDOCRINE DISEASE: Reversible hypogonadotropic hypogonadism. *Eur J Endocrinol*. 2016. Jun;174(6):R267-74. doi: 10.1530/EJE-15-1033. Epub 2016 Jan 20. Review. PMID: 26792935.
29. Lamine F, Lalubin F, **Pitteloud N**, Burnier M, Zanchi A. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. *Swiss Med Wkly*. 2016. Feb 28;146:w14282. doi: 10.4414/smw.2016.14282. eCollection 2016. PMID: 26922155.
30. Phan-Hug F, Kraus C, Paoloni-Giacobino A, Fellmann F, Typaldou SA, Ansermet F, Alamo L, Eggert N, Pelet O, Vial Y, Muehlethaler V, Birraux J, Ramseyer P, Renteria SC, Dwyer A, **Pitteloud N**, Meyrat BJ. [Patients with variations of sex development: an example of interdisciplinary care]. *Rev Med Suisse*. 2016. Nov 9;12(538):1923-1929. French. PMID: 28696598.
31. Starnoni D, Daniel RT, Marino L, **Pitteloud N**, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. *Acta Neurochir (Wien)*. 2016. Nov;158(11):2109-2121. PMID: 27586125.
32. Cossu G, Daniel RT, Pierzchala K, Berhouma M, **Pitteloud N**, Lamine F, Colao A, Messerer M. Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. *Pituitary*. 2019. Nov 2. PMID: 30390277
33. Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamäki J, Raivio T, **Pitteloud N**. Clinical Management of Congenital Hypogonadotropic Hypogonadism. *Endocr Rev*. 2019. 40(2):669-710. PMID: 306986717
34. Subramanian M, Wojtuszczyzn A, Favre L, Boughorbel S, Shan J, Letaief KB, **Pitteloud N**, Chouchane L. Precision medicine in the era of artificial intelligence: implications in chronic disease management. *J Transl Med*. 2020. 18(1):472. PMID: 33298113
- 35.

### Invited Lectures: National (2010-present)

- |            |  |
|------------|--|
| 30.09.2010 | Diagnosis and genetic of hypogonadism. 4ème Journée d'Endocrinologie Vaud-Genève, Morges (invited lecture)   |
| 16.11.2010 | What is new in GnRH. Visiting Professor. Service Endocrinology & Pediatric Endocrinology, University Inselspital. Bern (invited lecture)   |
| 09.12.2010 | Percer les mystères de la puberté. Leçon inaugurale. CHUV  |
| 17.12.2010 | Des nouveaux gènes contrôlant la reproduction humaine et leur identification. Colloque scientifique de l'Unité de Médecine de la Reproduction. Maternité, CHUV (invited lecture) |
| 14.01.2011 | Role of FGF signaling in the neuroendocrine control of reproduction. Faber Foundation. Lausanne (invited lecture)  |
| 20.01.2011 | Prolactinome. Colloque cas Clinique. CHUV  |

- 31.01.2011 Role of FGF signaling in the neuroendocrine control of reproduction. Visiting professor seminar. Center for Integrative Genomics. Lausanne (invited lecture)
- 15.02.2011 Ménopause. Colloque cas Clinique. CHUV
- 19.03.2011 La transition de la pédiatrie vers les adultes. Conférence Turner Syndrome, Bussigny-sur-Lausanne (invited lecture)
- 01.04.2011 Diabétologie: Traitement basé sur les valeurs de laboratoire. Primary Care Academy. Montreux (invited lecture)
- 14.04.2011 Puberté tardive : clinique et génétique. Colloque d'endocrinologie pédiatrique. Lausanne (invited lecture)
- 18.04.2011 Hyperfonction et hypofonction surrénaliennes. Colloque PG du Dépt de Médecine. CHUV
- 19.05.2011 Genetics basis of hypogonadotrophic hypogonadism. Service d'endocrinologie, Hôpitaux Universitaires de Genève. Genève (visiting professor et invited lecture)
- 26.05.2011 Le principe d'action des incrétines et leur rôle dans le traitement du diabète de type 2. Symposia Novo Nordisk. Lausanne (invited lecture et moderator)
- 21.06.2011 Gynécomastie. Colloque vignette. CHUV
- 07.07.2011 Les diabètes avec accent sur MODY. Colloque cas clinique. CHUV
- 22.09.2011 L'obésité chez l'enfant et adolescent. Colloque d'endocrinologie pédiatrique, CHUV (co-organisator et moderator)
- 03.10.2011 Progress in the understanding of hypogonadotropic hypogonadism. Kinderspital Zürich, Zürich (visiting professor and invited lecture)
- 06.10.2011 Endocrinologie de la grossesse. Endocrinologie et grossesse. 5ème Réunion Vaud-Genève d'endocrinologie, Morges (invited lecture and co-organizer)
- 13.10.2011 Traitement des aspects métaboliques du syndrome des ovaires polykystiques. Polycystic Ovarian Syndrome (PCOS) Symposia. CHUV (invited lecture, moderator and organizer)
- 25.10.2011 Human GnRH deficiency: Deciphering molecular pathogenesis. Advanced cell culture techniques for tissue engineering and drug discovery and development. XXII. BD-STCS Workshop 2011, Bâle (invited lecture)
- 03.11.2011 Syndrome des ovaires polykystiques : identification, investigation et suivi. Colloques de l'Unité Multidisciplinaire de Santé des Adolescents (UMSA), CHUV (invited lecture)
- 08.11.2011 Discussion: importance and implications for daily practice. Advisory Brd Meeting "Degludec The future of insulin therapy, Morges
- 01.12.2011 Aspects cliniques du syndrome des ovaires polykystiques. Les rencontres de Prangins, Prangins, Suisse (invited lecture)
- 06.12.2011 Retard pubertaire et prise en charge. Vidéoconférence des hôpitaux de Suisse romande. Colloque de Pédiatrie, CHUV (invited lecture)

- 02.12.2011 Male hypogonadism. Session: Continuous Medical Education. Annual SGED Meeting, Berne (invited lecture)
- 19.01.2012 Puberté tardive – Kallmann – Projet Européen, Réunion annuelle SSEDP /SGPED, St-Sulpice
- 08.03.2012 Troubles du cycle chez la jeune femme. Place et importance du syndrome des ovaires polykystiques. Colloque de formation de la Sté Neuchâteloise de Médecine, Hôpital de Neuchâtel (invited lecture)
- 08.03.2012 Diabète et hypogonadisme : prise en charge. Journée Vaud-Genève de diabétologie 2012, Morges (invited lecture and co-organizer)
- 29.03.2012 Hypogonadisme chez l'homme. Sessions interactives avec cas pratiques. Symposium Médical de l'Institut Central (ICHV) 2012 : L'endocrinologie dans tous ses états. Clinique Romande de Réadaptation SUVA, Sion (invited lecture)
- 03.05.2012 Progrès récents dans la recherche des incrélines. Nouveautés dans le traitement du diabète de type 2. CHUV (invited lecture)
- 18.05.2012 FGF21 a link between metabolism and reproduction. Session: Human genetics and models. FGF Gordon Conference 2012, Les Diablerets (invited lecture)
- 07.06.2012 Registre européen – déficience en GnRH. Colloque cas clinique, CHUV
- 14.06.2012 Suivi Basedow en âge adulte. Colloque d'endocrinologie pédiatrique « Les troubles thyroïdiens ». CHUV (invited lecture)
- 30.07.2012 Pathologies hypophysaires et médecine interne. Colloque PG du Département de Médecine, CHUV
- 31.10.2012 Acromégalie. Colloque hebdomadaire du Service de Neurologie. CHUV
- 07.11.2012 Morbus Cushing : Statu quo et Prise en charge. Atelier Novartis Consultant Network « Syndrome de Cushing ». Lausanne (chair)
- 16.11.2012 PCO et syndrome métabolique. Les Journées NETTER de la Sté Européenne de Gynécologie, Montreux (invited lecture)
- 13.12.2012 Apport du diagnostic génétique pour les pathologies surrénaliennes. Pathologies surrénaliennes. 6ème Journée VD-GE Endocrinologie, La Longeraie, Morges (invited lecture et co-organizer)
- 04.09.2013 Role of FGF signaling in the neuroendocrine control of reproduction. Séminaire endocrinologie et Diabète Hôpital Universitaire de Bâle (invited lecture)
- 21.11.2013 Redefining syndromes in the era of exomes. Annual Symposium of the Swiss Endocrine society, Bern
- 12.12.2013 Fertilité : Evaluation et traitement de l'infertilité chez l'homme : le point de vue de l'endocrinologue. 7ème Journée VD-GE Endocrinologie, La Longeraie, Morges (invited lecture et co-organizer)
- 23.04.2015 Hirsutismus. Formation pour spécialistes FMH Endocrinologie / Diabétologie (FOSPED), Bienne, Switzerland

- 04.06.2015 Nouvelles stratégies thérapeutiques dans l'œdème maculaire diabétique. Hôpital ophtalmique Jules-Gonin, Lausanne (invited lecture)
- 23.06.2015 Traitement de fertilité dans l'hypogonadisme hypogonadotrope masculin. Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 27.10.2015 Déficit en testostérone et troubles métaboliques. Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 29.10.2015 Syndrome des ovaires polykystiques, entrave à la fertilité et haut risque cardiovasculaire sur la durée. 6ème Journée jurassienne d'endocrinologie et de diabétologie, Delémont
- 03.12.2015 Variations de la différenciation sexuelle (VDS) /Disorders of Sex Development (DSD): un challenge pour la transition (symposium, invited lecture and co-organizer)
- 14.01.2016 Diagnosis and treatment of hypogonadotropic hypogonadism. Women's Health Congress 2016, University Hospital, Basel (invited lecture)
- 02.02.2016 Acromégalie: nouveautés. Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 12.01.2017 Detection of polycystic ovaries early in puberty - does it make any difference? Women's Health Congress 2017, CHUV (Symposium)
- 26.01.2017 Endocrinologie de la reproduction. The Year in Endocrinology / Publications incontournables de l'année 2016 (symposium, invited lecture and co-organizer)
- 16.02.2017 Hypogonadisme chez l'homme (quand faut-il le chercher et qui substituer en testostérone?) Société vaudoise de médecine (Symposium)
- 02.03.2017 The Year in Diabetes / Publications incontournables de l'année 2016 (symposium, co-organizer)
- 06.04.2017 The Year in Obesity / Publications incontournables de l'année 2016 (symposium, co-organizer)
- 07.12.2017 Prolactinome: quand arrêter le traitement d'agonistes dopaminergiques. Rencontre endocrinologie-neurochirurgie (symposium lecture and co-organizer)
- 18.01.2018 Reproduction. The Year in Endocrinology / Publications incontournables de l'année 2017 (symposium lecture and organizer)
- 15.02.2018 The Year in Diabetes / Publications incontournables de l'année 2017 (symposium, co-organizer)
- 15.03.2018 The Year in Obesity / Publications incontournables de l'année 2017 (symposium, co-organizer)
- 13.09.2018 Infertilité dans les hypogonadismes hypogonadotropes : usage de la pompe à GnRH et des gonadotropines. Symposium Endocrinologie de la reproduction (lecture and co-organizer)

- 04.10.2018 Différences physiologiques entre hommes et femmes liées aux hormones et à l'activité physique, Réseau Romand de Médecine de l'Exercice et du Sport (RRMES) Symposium d'automne, Yverdon-les-Bains (invited lecture)
- 31.10.2018 Différences physiologiques entre hommes et femmes liées aux hormones : implication pour l'activité, CHUV, Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 13.11.2018 Progrès en endocrinologie. Forum pour la formation médicale FomF, Update Refresher en Médecine Interne, Beaulieu, Lausanne (invited lecture)
- 10.01.2019 Reproduction & pathologies hypophysaires. The Year in Endocrinology / Publications incontournables de l'année 2018 (symposium lecture and organizer)
- 16.01.2019 Syndrome des ovaires polykystiques. Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 14.02.2019 The Year in Diabetes / Publications incontournables de l'année 2018 (symposium, co-organizer)
- 14.03.2019 Obésité et hypogonadisme. The Year in Obesity / Publications incontournables de l'année 2018 (symposium lecture, co-organizer)
- 03.05.2019 Aménorrhée hypothalamique. 2<sup>ème</sup> Journée Update en PMA, Endocrinologie, Gynécologie et Ménopause, Lausanne (invited lecture)
- 19.06.2019 Endocrinologie pratique au moyen d'exemples de cas. Forum pour la formation médicale FomF, Update Refresher en Médecine Interne, Beaulieu, Lausanne (invited lecture)
- 04.07.2019 Perturbateurs endocriniens. Centre Universitaire de médecine générale et santé publique (Unisanté) Lausanne (invited lecture)
- 15.11.2019 Gynecomastia and puberty. Annual SGED Meeting, Bern (invited lecture)
- 30.01.2020 Reproduction & pathologies hypophysaires. The Year in Endocrinology / Publications incontournables de l'année 2019 (symposium lecture and co-organizer)
- 04.03.2020 Traitement de la ménopause. Séminaires hebdomadaires du Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV
- 19.11.2020 La prise en charge endocrinologique I, Programme Dysphorie de genre et prise en charge des demandes de réassignation sexuelle. CHUV (invited lecture)
- 04.02.2021 La prise en charge endocrinologique II, Programme Dysphorie de genre et prise en charge des demandes de réassignation sexuelle. CHUV (invited lecture)
- 12.02.2021 Maladies de l'hypophyse et des glandes surrénales. Forum pour la formation médicale FomF, Update Refresher en Médecine Interne, Livestream, Hôtel de la Paix, Lausanne (invited lecture)
- 19.03.2021 Régulation de l'axe hypothalamo-hypophysio-gonadique et aspects génétiques. CAS en gynécologie médicale et endocrinologie gynécologique, Université de Genève en visioconférence

- 09.12.2021 La prise en charge endocrinologique, Programme Dysphorie de genre et prise en charge des demandes de réassignation sexuelle. CHUV (invited lecture)
- 09.12.2021 Hirsutisme, Symposium d'endocrinologie, Morges (invited lecture)
- 11.12.2021 Cas d'exemple d'affections des glandes surrénales, FomF Update Refresher en Médecine Interne, Livestream, SwissTech Convention Center, Lausanne (invited lecture)
- 11.05.2022 L'endocrinologie en pratique à partir d'exemple de cas, FomF Update Refresher en Médecine Interne, Livestream, SwissTech Convention Center, Lausanne (invited lecture)
- 13.05.2022 Hypogonadisme chez l'homme : quel bilan et prise en charge ? FomF Endocrinologie – Diabétologie Update Refresher, Livestream, SwissTech Convention Center, Lausanne (invited lecture)

### **Invited Lectures: International (2010-present)**

- 22.09.2010 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), 49<sup>th</sup> Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Prague, Czech Republic (invited lecture)
- 01.03.2011 Role of FSH in human gonadal development: clinical implications for male fertility. University Tokyo, Japan (symposium)
- 20.05.2011 Gonadotropin sensitivity. 43<sup>rd</sup> International Symposia on GH and Growth Factors in Endocrinology and Metabolism (KICGS). Rome, Italy (invited lecture)
- 4-7.06.2011 Management of hypogonadism through puberty. Meet the Professor Lecture. 93<sup>rd</sup> Annual Meeting of the Endocrine Society. Boston, USA (invited lecture)
- 4-7.06.2011 Genetic susceptibility to hypothalamic amenorrhea. 93<sup>rd</sup> Annual Meeting of the Endocrine Society. Boston, USA (symposium)
- 27.09.2011 Monogenic disorders behind hypogonadotropic hypogonadism. Sandoz International Satellite Symposium, 50<sup>th</sup> annual meeting of the European Society for Paediatric Endocrinology ESPE 2011, Glasgow, UK (symposium)
- 20.10.2011 Complex genetics of human GnRH deficiency. Institute of Metabolic Science Seminar Series. Cambridge, UK (visiting professor)
- 29.10.2011 Hypogonadotropic hypogonadism. Panel discussion: Treatment of hypogonadotropic hypogonadism in male from childhood. 43<sup>rd</sup> International Symposium on Endocrinology and Metabolism, Tokyo, Japan (invited lecture)
- 10.11.2011 Novel insights into hypogonadotropic hypogonadism. 39<sup>th</sup> Meeting of the British Society for Paediatric Endocrinology and Diabetes. London, England (symposium)
- 25.02.2012 GnRH deficiency: clinical and genetic aspects. Assir Central Hospital, Abha, Arabia Saudia (visiting professor)
- 22.03.2012 Novel mutations causing infertility. Session: Clinical Management Workshop 3: Advances in assessment and management of infertility. Society for Endocrinology

- BES 2012, Harrogate, UK (symposium)
- 27.04.2012 Chez qui dépister un diabète ? 10<sup>th</sup> Swiss-Russian General Practitioners Conference 2012, St-Petersbourg, Russia (symposium)
- 05.05.2012 New mechanisms of hypothalamic amenorrhea. Symposium 49: Genetic breakthroughs in reproductive pathology and physiology. 15<sup>th</sup> International Congress of Endocrinology & 14<sup>th</sup> European Congress of Endocrinology. Florence, Italy (symposium)
- 20.05.2012 Genetics of idiopathic hypogonadotropic hypogonadism. Neuroendocrine Symposium, Shanghai, China (symposium)
- 12.09.2012 Functional Hypothalamic Amenorrhea: genetic basis. European NeuroEndocrine Association (Enea). Vienna, Austria (invited lecture)
- 28.09.2012 Clinical and genetic aspects of hypogonadotropic hypogonadism. 46<sup>th</sup> Annual Scientific Meeting of the Japanese Society for Pediatric Endocrinology, Osaka, Japan (symposium)
- 13.10.2012 Symposium on 'New Genetics of Familial Endocrinopathies' and Symposium on "Male infertility". 15<sup>th</sup> Annual Meeting of the Canadian Society of Endocrinology and Metabolism & the Canadian Diabetes Association, Vancouver, CAN (symposium)
- 28.11.2012 Delayed puberty. Symposium on Normal and abnormal development of the male reproductive tract. 7<sup>th</sup> European Congress of Andrology, Berlin (symposium)
- 19.01.2013 Hypogonadisme et diabète. Session on Diabetes and sexuality. Les XIV Rencontres Franco-Suisse (Sanofi-Aventis), Evian, France (symposium)
- 24.04.2013 Genetic basis of congenital hypogonadotropic hypogonadism. German Annual Meeting for Paediatric Endocrinology. Muenster, Germany (symposium)
- 25.05.2013 Hypogonadisme à l'âge adulte: Flashback sur la puberté. 5<sup>ème</sup> Symposium francophone (Novo Nordisk). Marseille, France (symposium)
- 30.08.2013 Oligogenicity in Congenital Hypogonadotropic Hypogonadism. European Joint Scientific Training School COST-FENS-IBRO, Prato, Italy (symposium)
- 21.09.2013 Genetic aspects of central hypogonadism in the male: The missing genotype-phenotype correlation. 5<sup>th</sup> International Symposium on Genetics of Male Infertility, Florence, Italy (symposium)
- 22.09.2013 Redefining syndromes in the era of exomes. 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (symposium)
- 06.10.2013 Congenital hypogonadotropic hypogonadism. British Society for Endocrinology Clinical Updates Course, Bristol, UK
- 22.11.2013 Histoire naturelle de pubertés retardées. 34<sup>ème</sup> Journées Guéritée, Paris, France (symposium)
- 06.06.2014 Hormonal control of spermatogenesis in men: Therapeutic aspects in hypogonadotropic hypogonadism. Les 57<sup>èmes</sup> Journées Internationales d'Endocrinologie Clinique H.P. Klotz, Paris, France (symposium)

- 08.07.2014 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH). 9<sup>th</sup> Annual Meeting of the European Neuroscience, Milan, Italy (symposium)
- 20.09.2014 Lessons drawn from gynaecological disorders in relation with hypothalamic-pituitary malfunction. 53<sup>rd</sup> Annual Meeting of the Society of Paediatric Endocrinology, Dublin, Ireland (symposium)
- 08.10.2014 FGF21: un lien entre reproduction et métabolisme. 31<sup>ème</sup> Congrès de la Société Française d'Endocrinologie, Lyon, France (symposium)
- 22.11.2014 Male hypogonadism: Pubertal development & fertility. 1<sup>st</sup> Sandoz Endocrinology Debate and Global Exchange, Vienna, Austria (symposium)
- 12.12.2014 Induction of spermatogenesis in men with hypogonadism. 9<sup>th</sup> Hammersmith Multidisciplinary Endocrinology Symposium. Hammersmith, UK (symposium)
- 18.02.2015 The genetics of hypogonadotropic hypogonadism in males and females. ESE Basic Endocrinology Course in Reproductive Endocrinology 2015. Edinburgh, UK.
- 03.02.2015 Use of Genomics in Elucidating Puberty. 14<sup>th</sup> International Pituitary Congress, San Diego, USA (symposium)
- 05.03.2015 FGF21: Metabolism and Reproduction. The Endocrine Society's 97<sup>th</sup> Annual Meeting and Expo (Endo 2015), San Diego, USA (symposium)
- 27.04.2015 NGS in the molecular diagnostic of CHH - exome vs targeted genes: What is the best strategy? COST Action BM1105 Joint Scientific Meeting & Training School, Monash University Prato Center, Prato, Italy (symposium)
- 02.10.2015 Pubertal Induction and Fertility Prospects in Males. 54<sup>th</sup> Annual Meeting of European Society for Pediatric Endocrinology, Barcelona, Spain (symposium)
- 03.11.2015 FGF's and Hypogonadism. Society for Endocrinology British Endocrine Society 2015, Edinburgh, UK (symposium)
- 11.11.2015 Hypogonadotropic hypogonadism: Etiology and treatment. Global Excellence Symposium in Growth and Reproduction, Copenhagen, Denmark (symposium)
- 27.01.2016 GnRH: An overview of its critical role in puberty and reproductive development. Royal Society of Medicine, London, UK (symposium)
- 04.09.2016 FGFR mutations in congenital hypogonadotropic hypogonadism. Joint meeting of the International Congress of Endocrinology (ICE) and the China Society of Endocrinology (CSE), Beijing, China (symposium)
- 23.09.2016 Gonadotrophin replacement for induction of fertility in hypogonadal men. 9<sup>th</sup> European Congress of Andrology (ECA2016) (Symposium)
- 28.01.2017 FGF21: a link between metabolism and reproduction. Matajca Day International Second Annual Meeting in Pediatric endocrinology, Bled, Slovenia (Symposium)
- 17.03.2017 Lecture 1: Hypogonadotropic hypogonadism. Finnish society for pediatric Endocrinology, Rovaniemi, Finland (Symposium)

- 17.03.2017 Lecture 2: Transition Clinic – Our experience. Finnish society for pediatric Endocrinology, Rovaniemi, Finland (Symposium)
- 21.05.2017 Pubertal induction and hormone replacement in young males. 19<sup>th</sup> European Congress of Endocrinology (ECE), Lisbon, Portugal (Symposium)
- 21.09.2017 FGF21: a peripheral hormone linking metabolism with reproduction in humans? 42<sup>ème</sup> Colloque de la Société de Neuroendocrinologie (SNE), Dijon, France (Symposium)
- 25.11.2017 Fertility and pregnancy in relation to hypogonadotropic hypogonadism. European Society of Endocrinology (ESE), Krakow, Poland (Symposium)
- 14.12.2017 Treatment of congenital hypogonadotropic hypogonadism. Masterclass fertility and pediatric endocrinology, Utrecht, The Netherlands (invited lecture)
- 06.03.2018 FN3 domain in the pathogenicity of CHH, 1<sup>st</sup> European Center for Reproductive Endocrinology (EUCRE) Conference, Monash University, Prato, Italy (invited lecture and co-organizer)
- 12.06.2018 Hypogonadotropic hypogonadism in adolescents. European masterclass on hypogonadotropic hypogonadism, Hoofddorp, The Netherlands (invited lecture)
- 29.11.2018 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), CNE, Pretoria, South of Africa (visiting professor)
- 30.03.2019 Les hypogonadismes hypogonadotropes réversibles. Les Chemins de Paris, Les Hormones de la puberté, Hôtel Pullman Tour Eiffel, Paris (invited lecture)
- 18.07.2019 Redefining syndromes at the era of whole genome sequencing. Pediatrics Grand Rounds Madison University Hospital, Madison Wisconsin, USA (visiting professor)
- 18.07.2019 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH). Primate Center Madison University, Madison Wisconsin, USA
- 17.08.2019 KS Patients information day. UCL Medical School Library, Royal Free Hospital, Hampstead, London (visiting professor)
- 02.09.2019 Overlap between CHH and Cornelia de Lange syndrome, 2<sup>nd</sup> European Center for Reproductive Endocrinology (EUCRE) Conference, Monash University, Prato, Italy (invited lecture and co-organizer)
- 19.10.2019 Hypogonadotropic hypogonadism from causes to treatment. Combined Endocrinology-Gynecology seminar, Porto, Portugal (visiting professor)
- 02.03.2020 Mini-Puberty. Horizon 2020, Lille, France (invited lecture)
- 09.10.2020 New genes involved in the hypogonadotropic hypogonadism, 36<sup>ème</sup> Congrès de la Société Française d'Endocrinologie (SFE), Marseille (invited lecture – virtual)
- 15.02.2021 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH). Postgraduated School of Endocrinology, University of Milano (invited lecture – virtual)
- 02.05.2022 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), Gordon Research Conference, Ciocco in Lucca (Italy)

- 21.05.2022 Decrease FGF signaling in human reproduction, European Congress of Endocrinology (ECE) Milano (invited lecture)
- 25.07.2022 Clinical spectrum of congenital hypogonadotropic hypogonadism, Lahore Children Hospital, Pakistan (visiting professor)
- 26.07.2022 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), CREM Center of Research in Excell in molecular biology, Lahore Pakistan (visiting professor)
- 27.07.2022 Clinical spectrum of congenital hypogonadotropic hypogonadism, Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), University of Islamabad, Pakistan (visiting professor)
- 29.07.2022 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), Aga Khan Medical Institute, Karachi, Pakistan (visiting professor)
- 30.07.2022 Genetic of Congenital Hypogonadotropic Hypogonadism (CHH), Dow Medical Center, Karachi, Pakistan (visiting professor)
- 07.08.2022 New genes controlling fertility, International Congress of Neuroendocrinology (ICN), Glasgow, UK (invited lecture)

## Major scientific achievements of Nelly Pitteloud

Prof. Pitteloud's major contributions to the field of reproductive endocrinology span the following areas:

i) Elucidating the genetic control of puberty and reproduction in humans, ii) redefining the genetic architecture of congenital hypogonadotropic hypogonadism (CHH), iii) transforming our understanding of the spectrum of human GnRH deficiency, iv) identifying predictors of outcome and testing novel therapies to treat infertility, v) discovering a novel link between reproduction and metabolism, vi) Defining a novel gatekeeper involved in the crosstalk between liver, microbiota, and brown adipose tissue and vii) international recognition and diffusion.

### ***i) Elucidating the genetic control of puberty and reproduction in humans***

The human disease model of patients with CHH has been a unique source of insight into the genetic control of puberty and reproduction in humans. The study of patients with rare mutations in genes regulating GnRH secretion and action has led to major insights into the physiology of reproduction with potential for the treatment of infertility. Over the last 25 years, genetic studies using cytogenetics, linkage analysis or candidate gene approaches have identified >25 loci comprising rare, high-impact variants underlying CHH. Prof. Pitteloud has been a leader in a number of these important gene discoveries. Notably, her work has deepened our understanding of the critical role of the FGF signaling pathway in reproduction (i.e. FGF8/FGFR1 signaling pathway with mutations in *FGFR1*, *FGF8*, *FGF17*, *HS6ST1*, the *FGF8* synexpression group (1,2,3,4)). More recently, Pr. Pitteloud' laboratory has discovered mutations in genes encoding fibronectin-3 (FN3) domains (*DCC*, *NTN1*, *NDNF*, *PLXNA1*) (22,23,24) in CHH, with a crucial role of these genes in GnRH neuron migration.

### ***ii) Redefining the architecture of CHH***

Observations of low penetrance and variable expressivity have long puzzled investigators examining the genetics of CHH. Prof. Pitteloud introduced the innovative notion of digenicity and oligogenicity as an explanation hypothesizing then demonstrating that CHH is not strictly a monogenic disorder (5,6,7). Indeed her lab and others have shown that the genetic architecture of CHH is complex, implicating multiple gene defects in each patient (i.e. oligogenicity) (5,6). Further, CHH presents with several associated phenotypes such as anosmia, cleft palate, hearing loss (8). Recently, we and others have shown that the disease subphenotypes can guide targeted gene identification (1,5,8) with implications for genetic testing and counseling. Our reports of phenotypic and genetic overlap between CHH and other syndromes such as CHARGE syndrome (14), septo-optic dysplasia, combined pituitary hormone deficiency (10), holoprosencephaly (2) and split hand-foot malformation (1) challenge current disease nosology.

### ***iii) Transforming our understanding of the spectrum of GnRH deficiency***

Prof. Pitteloud's work has helped elucidate the phenotypic spectrum of CHH (9) as well as work demonstrating that CHH and KS are not distinct clinical entities as previously thought (10). Further, her work has expanded the view for GnRH deficiency with the notion that milder forms of GnRH deficiency can manifest as constitutional delay of growth and puberty (CDGP); adult onset hypogonadotropic hypogonadism (AHH) in men (11) and hypothalamic amenorrhea (HA) in women (12). Indeed the Pitteloud team and others have shown these disorders to be variants across a spectrum of GnRH deficiency. Moreover, Prof Pitteloud's 2007 New England Journal of Medicine article demonstrating CHH reversal in adult life in 10% of patients (13) has completely transformed

the view of CHH from a lifelong disease to a plastic phenotype depending on environmental exposures; this is also supported by our discovery of genetic susceptibility to HA (12).

***iv) Identifying predictors of outcome and testing novel therapies to treat infertility***

Even though GnRH deficiency is a treatable form of infertility, Prof. Pitteloud identified that 30% of CHH patients remain infertile (9). Moreover, she identified critical predictors of outcome that help guide therapeutic management in the field. By deepening her investigation she used pulsatile GnRH therapy to unmask additional defects in the hypothalamic-pituitary-gonadal axis (15). These additional pituitary and gonadal defects account for some of these treatment failures, unmasked by GnRH treatment. Subsequently, she developed a novel approach to maximize fertility in the most severe cases of GnRH deficiency using a sequential approach (pre-treatment with rFSH) (16). She tested this innovative strategy in a pilot study that showed promising results (17). She led the international group in drafting and publishing the Nature Reviews Endocrinology Consensus Statement on approach to Diagnosis and treatment of CHH that was published in 2015 (18).

***v) Discovering a novel link between reproduction and metabolism***

Reproductive fitness is known to be tightly linked to energy availability, although the exact molecular mechanisms are still unknown. Through human genetics, we discovered mutations in *KLB* encoding  $\beta$ -Klotho, the obligate co-receptor mediating FGF21 signaling, in patients with CHH and a high frequency of associated metabolic defects. These mutations are loss-of-function and impair FGF21 signaling (19). Further, we reported that *Klb*-deficient mice also exhibit delayed puberty and subfertility partly due to a hypothalamic defect, and that FGF21 reach the hypothalamus through the fenestrated capillaries of the median eminence. Thus, the hepatokine FGF21, a key central metabolic regulator, appears to constitute another critical link between metabolism and reproduction.

***vi) Defining a novel gatekeeper involved in the crosstalk between liver, microbiota, and brown adipose tissue***

The study of the metabolic phenotype of  $\beta$ -Klotho deficient mice led to an expected finding; these mice were resistant to diet-induced obesity (DIO), although they lack FGF21 signaling pathway. These mice exhibited enhanced energy expenditure and BAT activity. Further they show not only an increase but also a shift in bile acid (BA) composition featured by activation of the classical (neutral) BA synthesis pathway at the expense of the alternative (acidic) pathway. High hepatic production of cholic acid (CA) results in a large excess of microbiota-derived deoxycholic acid (DCA). DCA is specifically responsible for activating the TGR5 receptor that stimulates BAT thermogenic activity. In fact, combined gene deletion of *Klb* and *Tgr5* or antibiotic treatment abrogating bacterial conversion of CA into DCA both abolish DIO resistance in *Klb*<sup>-/-</sup> mice (20,21). These data demonstrated that gut microbiota can regulate host thermogenesis via conversion of primary into secondary BA and have critical impact on metabolic phenotypes. Pharmacological or nutritional approaches to selectively modulate gut microbiota may have critical impact on metabolic disorders.

***vii) International recognition and diffusion***

In 2012, in recognition of her research accomplishments, Prof. Pitteloud was nominated in the Swiss Academy of Science. In parallel, she initiated (and chairs) a European consortium to study GnRH biology (COST Action BM1105) that includes >150 investigators spanning 28 countries. This Action has: i) established a European patient registry for GnRH deficiency; ii) received external funding for new research collaborations; iii) held three training schools and iv) produced a consensus statement on the diagnosis and treatment of GnRH deficiency (18). Recently, she is a founding member for the European Center for Reproductive Endocrinology.

- (1) Villanueva, C., et al., *Genet Med*, 2015. 17(8): p. 651-9
- (2) McCabe, MJ, et al., *J Clin Endocrinol Metab*, 2011. 96(10): p. E1709-18
- (3) Falardeau, J., et al., *J Clin Invest*, 2008. 118(8): p. 2822-31
- (4) Miraoui, H., et al., *Am J Hum Genet*, 2013. 92(5): p. 725-43
- (5) Pitteloud, N., et al., *J Clin Invest*, 2007. 117(2): p. 457-63
- (6) Sykiotis, G.P., et al., *Proc Natl Acad Sci U S A*, 2010. 107(34): p. 15140-4
- (7) Avbelj Stefanija, M., et al., *Hum Mol Genet*, 2012. 21(19) :p.4314-24
- (8) Costa-Barbosa, F.A., et al., *J Clin Endocrinol Metab*, 2013. 98(5): p. E943-53
- (9) Pitteloud, N., et al., *J Clin Endocrinol Metab*, 2002. 87(9): p. 4128-36
- (10) Raivio, T., et al., *J Clin Endocrinol Metab*, 2012. 97(4): p. E694-9
- (11) Dwyer, A.A., et al., *J Clin Endocrinol Metab*, 2010. 95(9): p. 4235-43
- (12) Caronia, L.M., et al., *N Engl J Med*, 2011. 364(3): p. 215-25
- (13) Raivio, T., et al., *N Engl J Med*, 2007. 357(9): p. 863-73
- (14) Jongmans, M.C., et al., *Clin Genet*. 2009. 75(1):65-71
- (15) Sykiotis, G.P., et al., *J Clin Endocrinol Metab*, 2010. 95(6): p. 3019-27
- (16) Dwyer, A.A., et al., *Best Pract Res Clin Endocrinol Metab*. 2015. 29(1):91-103
- (17) Dwyer, A.A., et al., *J Clin Endocrinol Metab*, 2013. 98(11): p. E1790-5
- (18) Boehm, U., et al., *Nat Rev Endocrinol*. 2015. 11(9):547-64
- (19) Xu, C., et al., *EMBO Molecular Medicine*, 2017. 9: p. 1379-1397
- (20) Somm, E., et al., *JCI insight*, 2017. 20; p. 2(8)
- (21) Somm, E., et al., *Am J Physiol Endocrinol Metab*, 2018. 315(5):E833-E847
- (22) Marcos, S., et al., *Hum Mol Genet.*, 2017. 26(11):2006-2017
- (23) Bouilly, J., et al., *Hum Mol Genet*. 2018. 27(2):359-372.
- (24) Messina, A., et al., *Am J Hum Genet*. 2020. 106(1):58-70.